Current Report Filing (8-k)
February 17 2017 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
February 13, 2017
Date of Report (Date of earliest event reported)
GALECTIN
THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
NEVADA
|
|
001-31791
|
|
04-3562325
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240
NORCROSS, GA 30071
(Address of Principal Executive Offices) (Zip Code)
(678)
620-3186
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.03. Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year.
On February 13, 2017, the Company filed with the Secretary of State of the State of Nevada Certificate of Designation of Preferences, Rights and
Limitations of Common Stock (Class W), establishing the terms of the Common Stock (Class W). A copy of the Certificate of Designation of Preferences, Rights and Limitations of Common Stock (Class W) is included as an exhibit to this report and is
incorporated by reference into this Item 5.03.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Exhibit Title or Description
|
|
|
3.1
|
|
Certificate of Designation of Preferences, Rights and Limitations of Common Stock (Class W)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
GALECTIN THERAPEUTICS INC.
|
|
|
By:
|
|
/S/ Jack W. Callicutt
|
|
|
Name: Jack W. Callicutt
|
|
|
Title: Chief Financial Officer
|
Date: February 17, 2017
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Exhibit Title or Description
|
|
|
3.1
|
|
Certificate of Designation of Preferences, Rights and Limitations of Common Stock (Class W)
|
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024